Abstract:Junbin Wang1,2 ,* Jin Gao1 ,* Qinnan Chen,1 Weiyan Zou,3 Fen Yang,4 Chenchen Wei,1 Zhaoxia Wang1 1Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, People’s Republic of China; 2Department of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, People’s Republic of China; 3Department of Histology and Embryology, Bengbu Medical College, Bengbu 233030, People’s Republic of China; 4Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhaoxia Wang; Chenchen WeiDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, No. 121 Jiangjiayuan Road, Nanjing City, Jiangsu Province 210011, People’s Republic of ChinaEmail zhaoxiawang66@126.com; weichenchen1990@126.comBackground: Long non-coding RNAs (lncRNAs) have been found to contribute to cisplatin resistance in several cancers; however, the role of lncRNA LINC01116 in cisplatin resistance remains unknown in non-small-cell lung cancer. This study aimed to examine the contribution of LINC01116 to cisplatin resistance in lung adenocarcinoma (LAD).Materials and Methods: Cisplatin-resistant A549/DDP cells were generated by treatment with cisplatin by dose escalation. LINC01116 expression was compared between A549 and A549/DDP cells, and between cisplatin-resistant and non-resistant LAD specimens. The cell viability, colony formation, proliferation, migration and invasion were measured using MTT and Transwell assays, and cell apoptosis and cell cycle were detected using flow cytometry. The expression of E-cadherin and Vimentin was quantified. LAD xenografts were modeled in nude mice to investigate the role of LINC01116 on the resistance of LAD to cisplatin.Results: MTT assay measured the IC50 values of 13.49 ± 1.62 and 3.52 ± 1.33 μg/mL for A549/DDP and A549 cells, respectively. LINC01116 was overexpressed in cisplatin-resistant LAD specimens and A549/DDP cells (P < 0.05). Knockdown of LINC01116 inhibited cell viability, proliferation, migration and invasion, promoted apoptosis and enhanced the sensitivity to cisplatin in A549/DDP cells, while LINC01116 overexpression promoted cell viability, proliferation, migration and invasion, inhibited apoptosis and reduced the sensitivity to cisplatin in A549 cells. LINC01116 knockdown resulted in a 2.1-fold increase in E-cadherin expression and a 56% reduction in Vimentin expression in A549/DDP cells, and LINC01116 overexpression resulted in a 45% reduction in E-cadherin expression and a 1.82-fold increase in Vimentin expression in A549 cells.Conclusion: Dysregulation of lncRNA LINC01116 expression results in resistance of LAD to cisplatin via the EMT process. Our findings support the oncogenic role of LINC01116 to promote the development of cisplatin resistance in LAD, and LINC01116 may be a novel predictor of poor response to cisplatin.Keywords: lung adenocarcinoma, cisplatin, chemotherapy resistance, LINC01116, epithelial–mesenchymal transition

Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma

LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma

Long Noncoding RNA LINC01426 Promotes the Progression of Lung Adenocarcinoma Via Regulating Mirna-125A-5p/ Casein Kinase 2 Alpha 1 Axis

A Novel Long Non-Coding RNA LINC00355 Promotes Proliferation of Lung Adenocarcinoma Cells by Down-Regulating Mir-195 and Up-Regulating the Expression of CCNE1.

Hypomethylation‐associated LINC00987 downregulation induced lung adenocarcinoma progression by inhibiting the phosphorylation‐mediated degradation of SND1

Long non‐coding RNA H19 is responsible for the progression of lung adenocarcinoma by mediating methylation‐dependent repression of CDH1 promoter

The Long Noncoding RNA LINC00665 Facilitates c-Myc Transcriptional Activity via the miR-195-5p MYCBP Axis to Promote Progression of Lung Adenocarcinoma

LINC01207 Promotes the Progression of Non-Small Cell Lung Cancer Via Regulating ARHGAP11A by Sponging Mir-525-5p

LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer

LINC00943 Regulates Mir-1252-5p/ywhah Axis to Promote Tumor Proliferation and Metastasis in Lung Adenocarcinoma

Upregulation of Long Intergenic Noncoding RNA 00673 Promotes Tumor Proliferation Via LSD1 Interaction and Repression of NCALD in Non-Small-cell Lung Cancer.

Epigenetic regulation of LINC01270 in breast cancer progression by mediating LAMA2 promoter methylation and MAPK signaling pathway

LncRNA LINC00525 suppresses p21 expression via mRNA decay and triplex‐mediated changes in chromatin structure in lung adenocarcinoma

LINC00115 regulates lung adenocarcinoma progression via sponging miR-154-3p to modulate Sp3 expression

Long Non-Coding RNA LINC01116 is Activated by EGR1 and Facilitates Lung Adenocarcinoma Oncogenicity Via Targeting Mir-744-5p/cdca4 Axis

Abnormal methylation mediated upregulation of LINC00857 boosts malignant progression of lung adenocarcinoma by modulating the miR‐486‐5p/NEK2 axis

Long Intergenic Non‑coding RNA 00467 Promotes Lung Adenocarcinoma Proliferation, Migration and Invasion by Binding with EZH2 and Repressing HTRA3 Expression.

The Long Intergenic Noncoding RNA 00707 Promotes Lung Adenocarcinoma Cell Proliferation and Migration by Regulating Cdc42.

LINC02418 promotes malignant behaviors in lung adenocarcinoma cells by sponging miR-4677-3p to upregulate KNL1 expression

Linc00673-V3 Positively Regulates Autophagy by Promoting Smad3-mediatedLC3Btranscription in NSCLC

Expression profiles of long noncoding RNAs in lung adenocarcinoma.